Scientists test drug duo to control Tough-to-Treat fat tissue cancers
NCT ID NCT04794127
Summary
This study tested whether adding a diabetes drug (pioglitazone) to a standard chemotherapy (trabectedin) could better control advanced liposarcoma, a rare cancer of fat tissue. It involved patients whose cancer had stopped responding to the standard drug alone. The goal was to see if the combination could shrink tumors or stop their growth more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPOSARCOMA, DEDIFFERENTIATED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Istituto Nazionale Tumori
Milan, MI, 20133, Italy
Conditions
Explore the condition pages connected to this study.